SCYNEXIS (SCYX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

SCYNEXIS (SCYX) - corporate logo

SCYNEXIS, Inc. (SCYX) relies on a sovereign development cycle, which makes the business resilient to macroeconomic shocks and transforms it into a defensive asset. The company is scaling the rollout of its products into global markets through a strategic alliance with GSK. The EV/EBITDA market trend, visualized in monetary terms, stands at 0.00, confirming the pricing dominance of the Brexafemme brand due to its innovative approach to fungal pathology therapy.

SCYNEXIS - SCYX Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for scynexis.com (SCYX)

- current price and projected stock value:
Stock Price SCYNEXIS|SCYX - Analyst Median Target
- market capitalization details:
Market Value SCYX|SCYX - Business Value
- book value of equity indicators:
Book Value per Share SCYNEXIS|SCYX - Net Asset Value|Market Capitalization to Book Value Ratio scynexis.com|SCYX - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital SCYNEXIS, Inc.|SCYX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio SCYNEXIS|SCYX - Company Cumulative Indebtedness|Debts to Book Capitalization SCYX|SCYX - Long-Term Debt Volume|Company Short-Term Debt SCYNEXIS|Quick Liquidity scynexis.com
- financial results and valuation multiples details:
SCYX - Company Profit|Expected Profit SCYNEXIS, Inc.|SCYX - Business Payback Period|Future Price to Earnings SCYNEXIS|SCYX - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple SCYX|SCYX - Operating profit before deduction of amortization|Net earnings per share for the last 12 months SCYNEXIS|SCYX - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months scynexis.com|SCYX - Earnings per share growth this year|Earnings growth forecast for next year SCYNEXIS, Inc.
General company analysis:Scynexis SCYX
Product sample of SCYNEXIS Inc

This multiple compares the total enterprise value, including net debt, to earnings before interest, taxes, depreciation, and amortization, allowing for an assessment of the real value of assets regardless of the debt load. By analyzing the historical EV/EBITDA trend of SCYNEXIS, Inc. (SCYX), an investor can correlate the market valuation of SCYNEXIS, Inc. (SCYX) with the production efficiency of its proprietary antimycotics, identifying entry points during price contractions or risks of margin compression.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - EV/EBITDA Multiple|Company Value to EBITDA AN2 Bio ANTX|EV/EBITDA Multiple PYPD|Enterprise Value to EBITDA Ratio ysbiopharm.com LSB|Iterum Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PHGE (BiomX Inc)|BioPharma Bio - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)